Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + Metformin in Recurrent Ovarian Clear Cell Carcinoma
NCT05759312Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of zimberelimab in ovarian clear cell carcinoma (OCCC), sponsored by Fudan University. Status: unknown.
02
Drugs
zimberelimab
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT05759312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759312.